J-H Deng1, J Deng, D-H Shi, X-N Ouyang, P-G Niu. 1. Department of Pharmacy, Fujian Provincial Maternal and Child Health Hospital, 18 Daoshan Road, Fuzhou, Fujian, China.
Abstract
INTRODUCTION: This study is to evaluate the association of polymorphisms of glutathione S-transferase P1 (GSTP1), copper-transporting P-type adenosine triphosphatase A (ATP7A) and X-ray repair cross-complementing group 1 (XRCC1) with the efficacy and toxicity of cisplatin-based treatment in advanced non-small cell lung cancer (NSCLC) patients. MATERIALS AND METHODS: The outcomes of 97 advanced non-small cell lung cancer patients treated with cisplatin-based chemotherapy were estimated. GSTP1, ATP7A, and XRCC1 genetic polymorphisms were determined via polymerase chain reaction of restriction fragment length polymorphism (PCR-RFLP) and DNA sequencing. Association of the polymorphisms with the efficacy and toxicity of cisplatin was analyzed, respectively. RESULTS: Significant associations were observed between GSTP1 A313G and response rate (RR) (p = 0.027), disease control rate (DCR) (p = 0.019), and progression-free survival (PFS) (p = 0.044), respectively. Patients with AG and GG of GSTP1 have notably lower risk of anemia (p = 0.046). XRCC1 A1196G was associated with the incidence of lymphopenia (p = 0.024) and diarrhea (p = 0.020). ATP7A C2299G was not related with RR, DCR, PFS, and the risk of toxicity. CONCLUSIONS: Advanced NSCLC patients with AA genotype of GSTP1 would obtain better curative effect followed with more risk of anemia when treated by cisplatin-based chemotherapy. ATP7A C2299G does not impact the efficacy and toxicity of cisplatin-based chemotherapy. XRCC1 1196A allele could predict the incidence of lymphopenia and diarrhea.
INTRODUCTION: This study is to evaluate the association of polymorphisms of glutathione S-transferase P1 (GSTP1), copper-transporting P-type adenosine triphosphatase A (ATP7A) and X-ray repair cross-complementing group 1 (XRCC1) with the efficacy and toxicity of cisplatin-based treatment in advanced non-small cell lung cancer (NSCLC) patients. MATERIALS AND METHODS: The outcomes of 97 advanced non-small cell lung cancerpatients treated with cisplatin-based chemotherapy were estimated. GSTP1, ATP7A, and XRCC1 genetic polymorphisms were determined via polymerase chain reaction of restriction fragment length polymorphism (PCR-RFLP) and DNA sequencing. Association of the polymorphisms with the efficacy and toxicity of cisplatin was analyzed, respectively. RESULTS: Significant associations were observed between GSTP1A313G and response rate (RR) (p = 0.027), disease control rate (DCR) (p = 0.019), and progression-free survival (PFS) (p = 0.044), respectively. Patients with AG and GG of GSTP1 have notably lower risk of anemia (p = 0.046). XRCC1A1196G was associated with the incidence of lymphopenia (p = 0.024) and diarrhea (p = 0.020). ATP7AC2299G was not related with RR, DCR, PFS, and the risk of toxicity. CONCLUSIONS: Advanced NSCLCpatients with AA genotype of GSTP1 would obtain better curative effect followed with more risk of anemia when treated by cisplatin-based chemotherapy. ATP7AC2299G does not impact the efficacy and toxicity of cisplatin-based chemotherapy. XRCC1 1196A allele could predict the incidence of lymphopenia and diarrhea.
Authors: Daniela F Giachino; Paolo Ghio; Silvia Regazzoni; Giorgia Mandrile; Silvia Novello; Giovanni Selvaggi; Dario Gregori; Mario DeMarchi; Giorgio V Scagliotti Journal: Clin Cancer Res Date: 2007-05-15 Impact factor: 12.531
Authors: Songjian Chen; Xia Huo; Yi Lin; Hao Ban; Yincheng Lin; Weiqiu Li; Bao Zhang; William W Au; Xijin Xu Journal: Int J Hyg Environ Health Date: 2010-03-01 Impact factor: 5.840
Authors: Richard Booton; Richard Booten; Tim Ward; Jim Heighway; Linda Ashcroft; Julie Morris; Nicholas Thatcher Journal: J Thorac Oncol Date: 2006-09 Impact factor: 15.609
Authors: Macus Tien Kuo; Helen H W Chen; Im-Sook Song; Niramol Savaraj; Toshihisa Ishikawa Journal: Cancer Metastasis Rev Date: 2007-03 Impact factor: 9.264
Authors: Penelope A Bradbury; Matthew H Kulke; Rebecca S Heist; Wei Zhou; Clement Ma; Wei Xu; Ariela L Marshall; Rihong Zhai; Susanne M Hooshmand; Kofi Asomaning; Li Su; Frances A Shepherd; Thomas J Lynch; John C Wain; David C Christiani; Geoffrey Liu Journal: Pharmacogenet Genomics Date: 2009-08 Impact factor: 2.089
Authors: M Tiseo; P Bordi; B Bortesi; L Boni; C Boni; E Baldini; F Grossi; F Recchia; F Zanelli; G Fontanini; N Naldi; N Campanini; C Azzoni; C Bordi; A Ardizzoni Journal: Br J Cancer Date: 2013-04-02 Impact factor: 7.640
Authors: Luis M Polo; Yingqi Xu; Peter Hornyak; Fernando Garces; Zhihong Zeng; Richard Hailstone; Steve J Matthews; Keith W Caldecott; Antony W Oliver; Laurence H Pearl Journal: Cell Rep Date: 2019-01-15 Impact factor: 9.423
Authors: R Mlak; P Krawczyk; M Ciesielka; P Kozioł; I Homa; T Powrózek; M Prendecka; J Milanowski; T Małecka-Massalska Journal: Clin Transl Oncol Date: 2015-12-09 Impact factor: 3.405